Treeway announces License and Collaboration Agreement with uniQure to develop a Gene Therapy for Amyotrophic Lateral Sclerosis (ALS)
Rotterdam, 14 January 2015 – Treeway B.V., founded by entrepreneurs Bernard Muller and Robbert Jan Stuit, both diagnosed with ALS, have announced a collaboration with uniQure N.V., a leading gene therapy company, (NASDAQ:QURE), to develop a gene therapy treatment for ALS.
Under the terms of the licensing and collaboration agreement, uniQure has granted Treewayan exclusive license in this field to uniQure’s relevant AAV5 viral vector and GDNF (Glial cell-derived neurotrophic factor) intellectual property. Treeway is responsible for the preclinicaland clinical development of the ALS gene therapy treatment. uniQure will provide Treeway with its manufacturing capabilities and will further collaborate with Treeway on ALS gene therapy development. Treeway and uniQure will jointly commercialize any resulting ALSgene therapy with defined geographical rights for commercialization assigned to each company. Financial details of the agreement have not been disclosed.
Inez de Greef, CEO of Treeway, is very pleased about this licensing, collaboration, and comarketingagreement as it represents a major milestone in executing its mission to developALS therapy. “Gene therapy is an innovative and viable technology for developing an ALS therapy and has the potential to change the disease course of ALS. A collaboration betweenTreeway and uniQure will accelerate this development by bringing two unique companies together,” says Ms. de Greef.
Jörn Aldag, CEO of uniQure, adds: “We are impressed by the immense energy and willpower of the Treeway founders in seeking a cure for ALS. We believe that by combining theirdisease know-how and uniQure’s gene therapy platform and expertise, we can jointly achieve a step forward in the way ALS is treated in the future”.